Humana Inc. (HUM) Stock Price & How to Invest

Humana Inc. is a Louisville-based health and well-being company best known as one of the two largest Medicare Advantage insurers in the country, alongside UnitedHealth. Its Insurance segment covers roughly 7.1 million individual and group Medicare Advantage members as of early 2026, plus Medicaid, military (TRICARE), and pharmacy-benefit members. The core economics turn on the medical loss ratio, the share of premium dollars paid out as medical claims, and on CMS star ratings, which determine quality-bonus payments that fund richer plan benefits.

The medical-cost trend is the dominant risk: when seniors use more care than priced for, the medical loss ratio rises and margins compress, which is what drove recent earnings pressure. Star ratings are a second lever, since a slip in ratings reduces CMS quality-bonus payments and can force benefit cuts that hurt retention; Humana's ratings softened heading into 2026. Medicare Advantage reimbursement and broader healthcare policy are set by the government and can change rate updates, risk-adjustment rules, or audit intensity. Finally, aggressive membership growth or repricing can pressure profitability or cause member attrition if benefits are trimmed too far.

23 analysts publish price targets on HUM, averaging $407.83 against a $363.86 price as of August 2026, or +12.1%. The published targets run from $249.00 to $513.00, a moderate spread, and the ratings split 12 buy, 12 hold, 2 sell. Over the last six months there have been 11 raises and 1 cut among the published actions. A price target is what an analyst published on a date, not a prediction, and sell-side ratings skew positive across the whole market.

Read the full HUM forecast and price target for the target table, the recent rating actions by firm, and how the consensus has shifted.

We give no verdict on Humana Inc.. Both cases are real, which is why the question is contested at all, so here is the strongest version of each.

The case for buying. Demographic tailwind in Medicare Advantage. The US population aged 65 and older keeps growing, and a rising share of seniors choose Medicare Advantage over traditional Medicare. The most optimistic published target, $513.00, assumes this works close to its best case.

The case against. The medical-cost trend is the dominant risk: when seniors use more care than priced for, the medical loss ratio rises and margins compress, which is what drove recent earnings pressure. The most pessimistic target, $249.00, is roughly what HUM is worth if this bites instead.

Read the full bull and bear case on HUM, including what would have to change to break either one. Walnut is not an investment adviser.

A simple financial snapshot. These are approximations and refresh quarterly; for current figures see Humana Inc.'s investor relations page or your broker.

• Revenue (TTM): ~$130 billion
• Adjusted EPS (2026 guidance): ~$9.00 or more
• Medical loss ratio (2026 outlook): ~92.75%
• Dividend yield: ~1.5%
• Price/Earnings (TTM): ~40x
• Market capitalization: ~$45 billion

These figures are approximate and tied to the June 2026 asOf date; insurer earnings can move sharply quarter to quarter with the medical-cost trend, and the trailing P/E looks high mainly because recent profits are depressed. Check Humana's latest filings and a current quote before relying on any single number.

If you want HUM exposure as part of a larger bundle rather than directly, these ETFs hold it meaningfully. Weights are approximate and refresh quarterly.

Other names that sit close to HUM: same theme, named as a direct competitor, or held beside it in the same funds. Each entry says which. Worth a look if you are thinking about diversification within a thesis rather than concentration on one ticker.

There are three common ways to get HUM exposure. Buy shares (or fractional shares) directly at any major broker. Hold an ETF that includes it (FMDE), which spreads the position across many companies. Or build it into a focused thematic portfolio, so HUM sits alongside other stocks that express the same thesis.

Walnut takes the portfolio route. Describe a thesis where HUM fits (for example “AI infrastructure” or “dividend-growth large-caps”) and the AI proposes 5 to 6 constituents with target weights. You review the plan and fund it through your own broker when you're ready.

New to this? Start with how to invest in stocks, see how to analyze a stock with AI, or compare the best AI stock analyzers.

If you believe an aging US population keeps driving Medicare Advantage enrollment, that Humana can rebuild its margins back toward its targeted levels, and that CenterWell's pharmacy, primary-care, and home-health businesses add durable value, then HUM is a way to express that view. The counterweight is that profitability hinges on the medical-cost trend, star ratings, and government reimbursement, all of which are outside the company's full control. How it fits depends on your own goals, time horizon, and how much exposure you already have to healthcare and managed care.

Whether HUM is worth buying today depends more on your time horizon and what you already hold than on any single call. We walk through valuation, what would have to go right, and the risks in is HUM a buy or a sell?, and where the stock could go from here in the HUM stock forecast.

For income investors, whether HUM pays a dividend and how the payout looks is covered in does HUM pay a dividend? And to weigh HUM against a peer, read the full side-by-side comparisons: HUM vs UNH and HUM vs CVS.